ATG-008 (also known as CC-223) is an oral, second-generation mammalian target of rapamycin (mTOR) kinase inhibitor, which blocks both mTOR complex 1 (TORC1) and mTOR complex 2 (TORC2). It has demonstrated to induce tumor cell apoptosis and decrease tumor cell proliferation. We are in partnership with Celgene to develop, manufacture and commercialize this compound in 14 countries/regions in Asia.
mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/AKT/mTOR signaling pathway, which is dysregulated in approximately eighty percent of human cancers. mTOR links with other proteins and serves as a core component of two distinct protein complexes, TORC1 and TORC2, which regulate different cellular processes. Currently, two first-generation mTOR inhibitors (everolimus and temsirolimus), targeting solely TORC1, are marketed globally for multiple oncology indications.
ATG-008 is currently conducting registrational Phase 2/3 clinical studies for treatment of solid tumors in Asian countries and regions.